REDWOOD CITY, Calif.,
July 30, 2015 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced
that Urology Practice published results from the second
clinical utility study of the Oncotype DX® prostate
cancer test, showing that incorporation of the test's Genomic
Prostate Score (GPS) in treatment planning resulted in greater
recommendations and acceptance of active surveillance as initial
management of prostate cancer in low and low-intermediate risk
patients.
"Despite increasing awareness of active surveillance as a viable
alternative to immediate intervention in men with clinically
low-risk prostate cancer, its adoption has been limited largely due
to physician and patient concerns around the accuracy of disease
risk assessment," said Marc
Dall'Era, M.D., principal investigator of the study and vice
chair of Urology at the University of
California, Davis Comprehensive Cancer Center. "Our study
showed that incorporation of the Oncotype DX results into clinical
practice significantly increased the number of patients who chose
active surveillance and avoided the adverse impact on quality of
life that can result from invasive treatments, as well as their
associated costs."
The multi-center study included 211 patients from 10 sites
across the United States. The
review of patient charts showed a relative increase of 56 percent
in use of active surveillance in patients who received their
Oncotype DX GPS compared to patients from the same practices with
similar risk factors who were not tested.
Additionally, the results showed an increase in physician
recommendation of active surveillance that was consistent with a
previous prospective clinical study published earlier this year.
Together, the two published clinical utility studies demonstrate
that use of Oncotype DX changes both treatment recommendations and
actual treatment received, resulting in greater recommendation and
adoption of active surveillance.
"These data from actual patient charts add an important
real-life perspective on the value of our test," said Phil Febbo, M.D., chief medical officer, Genomic
Health. "Combined with 14 studies including more than 2,000
patients and a recent favorable draft local coverage determination
on Medicare coverage, we believe this publication further supports
our efforts to secure reimbursement for the Oncotype DX prostate
cancer test."
About Oncotype DX Prostate Cancer Test
The Oncotype
DX® portfolio of breast, colon and prostate cancer tests applies
advanced genomic science to reveal the unique biology of a tumor in
order to optimize cancer treatment decisions. The Oncotype DX
prostate cancer test identifies which clinically low-risk patients
are eligible for active surveillance, as well as those who may
benefit from immediate treatment by predicting disease
aggressiveness. With half a million patients tested in more than 90
countries, Oncotype DX testing has redefined personalized medicine
by making genomics a critical part of cancer diagnosis and
treatment. To learn more about the Oncotype DX prostate cancer
test, visit: www.OncotypeDX.com or
www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ:
GHDX) is the world's leading provider of genomic-based diagnostic
tests that address both the overtreatment and optimal treatment of
early-stage cancer, one of the greatest issues in healthcare today.
The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive
amounts of genomic data into clinically-actionable results for
treatment planning throughout the cancer patient's journey, from
diagnosis to treatment selection and monitoring. The company
is based in Redwood City, California, with European
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on Twitter: @GenomicHealth, Facebook,
YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of the test to
physicians, patients and payors. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the ability of test
results to change treatment decisions; the risks and uncertainties
associated with the regulation of the company's tests; the results
of clinical studies; the applicability of clinical study results to
actual outcomes; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop;
the risks of competition; unanticipated costs or delays in research
and development efforts; and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the year ended March 31, 2015. These
forward-looking statements speak only as of the date
hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/urology-practice-publishes-study-showing-oncotype-dx-increases-use-of-active-surveillance-in-prostate-cancer-patients-by-56-percent-300121019.html
SOURCE Genomic Health, Inc.